Combination treatment for advanced intrahepatic cholangiocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase III clinical trial evaluates the efficacy and safety of toripalimab combined with lenvatinib and gemcitabine-based chemotherapy as a first-line treatment for patients with unresectable advanced intrahepatic cholangiocarcinoma (ICC). Approximately 480 patients will be enrolled and randomly assigned to one of three treatment arms: the combination therapy, a placebo with chemotherapy, or a placebo with standard chemotherapy. The study aims to determine if the combination therapy improves outcomes compared to standard chemotherapy alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age of 18-75 years (inclusive), male or female;
2. Volunteer to participate in the study by signing the informed consent form and the ability to comply with the study protocol;
3. Advanced ICC with diagnosis confirmed by histology or cytology;
4. Stage II, III, or IV per TNM staging for ICC of the American Joint Committee on Cancer (AJCC) (8th edition, 2017). Those with Stage II or III should be determined to be unresectable by the investigator;
5. Patients with no prior systemic chemotherapy or targeted therapy or loco-regional therapy (including but not limited to transarterial chemoembolization, transarterial embolization, transarterial chemotherapy or transarterial radioembolization) for ICC. Patients with recurrent disease more than 6 months after completion of adjuvant chemotherapy following curative resection are eligible;
6. Measurable lesion per RECIST v1.1;
7. Child-Pugh class A with no history of hepatic encephalopathy;
8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1;
9. Life expectancy ≥12 weeks;

Exclusion Criteria:

1. Diagnosis of hepatocellular carcinoma (HCC), mixed cholangiocarcinoma and HCC, sarcomatoid hepatocellular carcinoma, or hepatic fibrolamellar carcinoma by histology or cytology;
2. History of malignancy other than ICC within 5 years prior to screening, with the exception of localized malignancies that have been cured, including non-melanoma skin cancers, cervical carcinoma in situ, breast carcinoma in situ, and papillary thyroid carcinoma;
3. Prior radiotherapy for ICC within 4 weeks prior to randomization;
4. Major surgical procedures within 4 weeks prior to randomization;
5. Side effects from prior therapy (except alopecia and pigmentation) that has not recovered to ≤ grade 1 (per NCI-CTCAE v5.0) or levels specified in the inclusion/exclusion criteria;
6. Uncontrolled pericardial effusion, pleural effusion, or clinically significant moderate or severe ascites that is symptomatic or requires thoracentesis or paracentesis during the screening phase for control of symptoms;
7. Gastrointestinal (GI) hemorrhage within 6 months prior to randomization and/or gastrointestinal varices that have not been assessed and treated, if appropriate, within 6 months prior to randomization.
8. Gastrointestinal or non-gastrointestinal fistula, gastrointestinal perforation, or abdominal abscess within 6 months prior to randomization;
9. Ongoing or a history of recurrent intestinal obstruction. Patients with a single episode of intestinal obstruction that has fully resolved following treatment are eligible allowed;
10. History of serious cardiovascular and cerebrovascular diseases:
11. Significant bleeding and coagulopathy or other evidence of bleeding diathesis, to include:
12. Pre-existing CNS metastases and/or meningeal metastases (including dural metastases and leptomeningeal metastases);
13. Serious non-healing wound, active ulcer, or untreated bone fracture;
14. Vaccination with live virus or bacteria within 30 days prior to randomization;
15. Active autoimmune disease or history of autoimmune disease

Where it's running

• Zhongshan Hospital affiliated to Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jiazheng Yan
• Email: jiazheng_yan@junshipharma.com
• Phone: +86 158 2259 6147

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Perioperative toripalimab plus lenvatinib for multi-stage clear cell kidney cancer

  This trial tests whether giving toripalimab with lenvatinib before surgery helps shrink or kill tumors in people with localized, locally advanced, or metastatic clear cell kidney cancer.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07571551

• Combination treatment for advanced intrahepatic cholangiocarcinoma and gallbladder cancer

  This study is testing a new combination treatment for people with advanced bile duct and gallbladder cancer to see if it can help them respond better to therapy and possibly become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tia · NCT06852287

• Combining D-TACE-HAIC with Envafolimab and Lenvatinib for treating advanced liver cancer

  This study is testing a new treatment combining D-TACE-HAIC, Envafolimab, and Lenvatinib to see if it helps people with advanced liver cancer that can't be surgically removed.

  Recruiting Fujian Provincial Hospital · Fuzhou, Fujian · NCT06643208

• Combined therapy for advanced intrahepatic cholangiocarcinoma

  This study is testing a new combination of chemotherapy and targeted therapy to see if it can help people with advanced bile duct cancer feel better and live longer.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06298968

• Neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma

  This study is testing a new combination of chemotherapy and targeted therapy to see if it helps people with a specific type of liver cancer avoid recurrence after surgery.

  Recruiting at 3 sites Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu and 2 other locations · NCT06208462

• Comparing two treatments for advanced liver cancer

  This study is testing if a combination of two treatments for advanced liver cancer can help patients live longer and respond better than just one of the treatments alone.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06201065

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.